Our Commitment to Excellence since 1996

Dr. David Karabelnik is an entrepreneur and corporate finance specialist in the life sciences and pharmaceutical sectors. He is the founder and CEO of Breslin AG. Previously, he founded and managed Breslin Biotech AG, a Swiss-based life sciences venture capital firm launched in partnership with Dresdner-Allianz. Dr. Karabelnik has held six board positions, including with GPC and 4SC, and has acted as an advisor and investor for Deutsche Bank and Commerzbank. Over the course of his career, he has successfully led two companies through initial public offerings.

Earlier in his career, Dr. Karabelnik worked with various biotech and venture capital firms in San Francisco. He also co-founded and led Anawa Laboratories, a Swiss contract research organization serving the pharmaceutical and biotechnology industries. Under his leadership, Anawa grew to 60 employees across Switzerland and Germany before being acquired by MDS Pharma Services.

Dr. Karabelnik holds a PhD in biochemistry from ETH Zurich, where his doctoral research focused on drug-induced lipidosis. He has held multiple post-doctoral teaching and research positions at both ETH Zurich and the University of Zurich.

Dr. Detlef Wollweber is an expert in the life sciences sector, with a focus on pharmaceuticals, medical technology, and agro-industries. His core competencies include strategy, business development, and financing.

He has been with Breslin since 2013 alongside running his own consulting practice. Prior to that, he served as CEO of Bayer Innovation GmbH and Bayer Innovation Ventures GmbH, and held advisory roles with Bayer Pharma AG, Bayer CropScience AG, Fraunhofer ISC (ongoing), and several start-ups.

Earlier, Dr. Wollweber was head of research at Bayer CropScience AG and held senior roles across Bayer’s research, manufacturing, and marketing divisions. He was also seconded to the International Food Policy Research Institute in Washington, DC.

He holds a diploma and PhD in organic chemistry from Ruhr University Bochum, is named on over 30 patents, and lectured at the University of Düsseldorf for more than a decade.

Klaus Berding brings over 25 years of experience in banking and consulting, with a focus on the life sciences and technology sectors. Since 2003, he has led his own corporate finance and advisory firm, LSFA – Life Science & Financing, and has been part of Breslin’s operating team since 2005.

He is a co-founder and board member of Amypopharma, an Italian spin-off from UNIMIB, and has served for more than a decade as a coach and expert reviewer at European venture capital events organized by TechTour.

Earlier in his career, Klaus held senior positions at Dresdner Kleinwort, beginning in equity research and later advancing to corporate finance. As SVP and Director in the Chemicals & Healthcare Industry Group, he helped expand the bank’s international equity and IPO business, including establishing a joint initiative with an Israeli investment bank. He participated in or led over 40 IPOs, capital market transactions, spin-offs, and M&A mandates.

Klaus holds an MBA from Ruhr University Bochum and a post-graduate degree from the DVFA (Association of German Investment Professionals). He has completed specialized training in life sciences business development and venture capital, and is a member of the House of Pharma, supporting innovation in Germany’s Rhein-Main life sciences ecosystem.

Dr. Martin Schnee is a financial analyst and advisor with a strong scientific background in chemistry and biotechnology. An associated partner at Breslin since 2010, he identifies and evaluates business opportunities across the life sciences and chemical sectors.

He is the founder of Schnee Research, a financial research firm focused on industrial chemistry and biotech, and collaborates with AlphaValue, Europe’s largest independent financial research company. His prior experience includes analyst roles at Commerzbank, research boutiques, and a rating agency, covering biotech, pharma, medtech, and chemicals.

Dr. Schnee holds a PhD in chemistry from Goethe University Frankfurt and is a certified credit and biotech equity analyst. He is a member of DVFA, GDCh, and CLIB, and serves as a non-executive director at a gene therapy biotech company in Germany.